Hepatican Ltd

Hepatican Ltd is exploiting academic research and early development, to produce a bedside treatment for liver failure that will reduce the need for liver transplant, making better use of scarce available donor organs. Its IP offering is considerable. Its first aim is to raise investment to enable a first-in-human clinical trial for safety, with an indication of efficacy.